Novartis announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million.
- Read more about FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/fda-approves-novartis-vijoice-alpelisib-as-first-and-only-treatment-for-select-patients-with-pik3ca-related-overgrowth-spectrum
No comments:
Post a Comment